EFFICIENCY OF PATHOGENETIC THERAPY OF PATIENTS WITH ISCHEMIC HEART DISEASE WITH INTESTINAL DYSBIOSIS AND NORMOBIOTSENOZOM
DOI:
https://doi.org/10.11603/2415-8798.2017.1.7539Keywords:
coronary heart disease, normobiotsenoz intestines, intestinal dysbiosis, dynamics, indicators of clinical and laboratory status.Abstract
Ischemic heart disease (IHD) is the main reason of cardiovascular mortality in Ukraine rates of which are not decreased.
The aim of the study – to learn the effectiveness of standard pathogenetic therapy of patients with ischemic heart disease with normobiotsenozom (NB) and dysbiosis (DB) gut.
Materials and Methods. The study involved 68 patients aged 50 to 65 years, including 20 % of women. Patients with IHD with postinfarction cardiosclerosis, chronic heart failure (CHF) II functional class (FC) (NYHA) and intestinal dysbiosis of the 1st and 2nd degree (n = 45) and patients comparable by gender, age, FC CHF group ( n = 23) of the intestine normobiotsenozom received standard treatment of chronic coronary artery disease. The duration of follow-up was 8 weeks.
Results and Discussion. We established standard therapy positive effect on the clinical course of the disease, lipid metabolism and lipid peroxidation, indicators of immune inflammation, systemic inflammatory response and antioxidant in both groups of patients. It was found that the presence of intestinal dysbiosis of the 1st and 2nd levels associated with a lesser degree of positive dynamics in most of these parameters.
Conclusions. The standard therapy of patients with ischemic heart disease with normobiocenosis and intestinal dysbiosis of the 1st and 2nd degrees accompanied by a positive impact on the clinical course of disease in a reduction in the number of angina attacks per week, increasing the distance test of 6–minute walking and improved psychological status.
References
Boytsov, S.A. (2013). Mekhanizmy snizheniya smertnosti ot ishemicheskoy bolezni serdtsa v raznykh stranakh mira [Mechanisms for reducing mortality from ischemic heart disease in different countries of the world]. Profilakticheskaya meditsina – Preventive Medicine, 5, 9-19 [in Russian].
Lupanov, V.P. (2013). Vtorichnaya medikamentoznaya profilaktika ishemicheskoy bolezni serdtsa i infarkta miokarda [Secondary pharmacological prophylaxis of coronary heart disease and myocardial infarction]. Meditsinskiy sovet – Medical Advice, 3, 86-91 [in Russian].
Kharchenko, N.V. (2015). Disbakterioz: bolezn ili simptomokompleks? [Disbacteriosis: disease or symptom complex?]. Ínfo-medíya «Zdorovia Ukrainy» medychnyi portal. 27.03 [in Russian].
Shilov, A.M., Petrukhina, N.B., Zorina, O.A., & Mariyanovskiy, A.A. (2014).
Disbioz pishchevaritelnogo trakta kak faktor riska v serdechno-sosudistom kontinuume: patofiziologiya i lecheniye [Dysbiosis of the digestive tract as a risk factor in the cardiovascular continuum: pathophysiology and treatment]. Lektsii dlya vrachey Kardiologiya i angiologiya. Effektivnaya farmakoterapiya – Lectures for doctors. Cardiology and Angiology. Effective Pharmacotherapy, 3, 44-52 [in Russian].
Kharchenko, N.V., Chernenko, V.V., Yankovskiy, D.S., Dyment, H.S. (2003). Rol kyshechnoy mikroflory v razvitii khronicheskikh zabolevaniy zheludochno-kishechnogo trakta [The role of the intestinal microflora in the development of chronic diseases of the gastrointestinal tract]. Zhurnal praktychnoho líkarya – Journal of Practical Doctor, 4, 20-27 [in Russian].
Lniavina, V.M. (2008). Izmeneniya lipidnogo obmena u bolnykh ishemicheskoy boleznyu serdtsa, assotsyyrovannoy s dysbiozom kyshechnika; metabolicheskiye éffekty probiotikov [Changes in lipid metabolism of patients with ischemic heart disease, associated with intestinal dysbiosis; metabolic effects of probiotics]. Candidate’s thesis. S. Peterburg: [in Russian].
Montalescot, G. & Sechtem, U. (2013). ESC guidelines on the management of stable coronary artery disease. Eur. Heart J. doi:10.1093/eurheartj/ent296.
Palaniswamy, C. & Aronow, W.S. (2011). Treatment of stable angina pectoris. Am. J. Ther. 5, (18), е138-е152.
Henderson, R.F. & O’Flynn, N. (2012). Management of stable angina: summary of NICE guidance. Heart, 98, 500-507.
Opie, L.Y. & Horowitz, J.D. (2012). Nitrates and newer anti-anginals. Drugs for the Heart. 8th ed: Elsevier.
Jonsson, G., Abdelnoor, M., & Muller, C. (2005). A comparison of the two beta-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical endpoints after myocardial infarction; a single-centre, randomized study of 232 patients // Cardiol. 3, (103), 148-155.
Fox K. (2006). Guidelines on the management of stable angina pectoris – executive summary. The Task Force on the Management of stable angina pectoris of the European Society of Cardiology. Eur. Heart J. 27, 1341-1381.
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal Advance Access, published June 8, 2-85.
Friedewald, W.T. R.I. Levy, & D.S. Fredrickson (1972). Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18, (6), 499.
Matteo Serino, Vincent Blasco-Baque, Simon Nicolas, & Remy Burcelin. (2014). Far from the Eyes, Close to the Heart: Dysbiosis of Gut Microbiota and Cardiovascular Consequences. Curr. Cardiol. Rep., 16 (11), 540.
Goldsmith, J.R, & Sartor, R.B. (2014). The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications. J Gastroenterol. 49 (5), 785-798.
Koeth, R.A, Wang, Z, Levison, B.S, Buffa, J.A, Org, E., & Sheehy, B.T. (2013). Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 19 (5), 576-585.
Tomasello, G., Bellavia, M., Palumbo, V.D., Gioviale, M.C., Damiani, P., Lo Monte, A.I. (2011). From gut microflora imbalance to mycobacteria infection: is there a relationship with chronic intestinal inflammatory diseases? Ann. Ital. Chir., 82 (5), 361-368.
Downloads
Published
How to Cite
Issue
Section
License
Authors who sent their manuscript to "Вісник наукових досліджень. Bulletin of Scientific Research" Surgery agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. 
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
